Title |
Bone marrow-derived cells for cardiovascular cell therapy: an optimized GMP method based on low-density gradient improves cell purity and function
|
---|---|
Published in |
Journal of Translational Medicine, September 2014
|
DOI | 10.1186/s12967-014-0276-0 |
Pubmed ID | |
Authors |
Marina Radrizzani, Viviana Lo Cicero, Sabrina Soncin, Sara Bolis, Daniel Sürder, Tiziano Torre, Francesco Siclari, Tiziano Moccetti, Giuseppe Vassalli, Lucia Turchetto |
Abstract |
Cardiovascular cell therapy represents a promising field, with several approaches currently being tested. The advanced therapy medicinal product (ATMP) for the ongoing METHOD clinical study ("Bone marrow derived cell therapy in the stable phase of chronic ischemic heart disease") consists of fresh mononuclear cells (MNC) isolated from autologous bone marrow (BM) through density gradient centrifugation on standard Ficoll-Paque. Cells are tested for safety (sterility, endotoxin), identity/potency (cell count, CD45/CD34/CD133, viability) and purity (contaminant granulocytes and platelets). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Scientists | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Poland | 1 | 3% |
Switzerland | 1 | 3% |
Unknown | 29 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 26% |
Student > Bachelor | 6 | 19% |
Student > Ph. D. Student | 5 | 16% |
Student > Master | 4 | 13% |
Other | 3 | 10% |
Other | 4 | 13% |
Unknown | 1 | 3% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 32% |
Agricultural and Biological Sciences | 6 | 19% |
Biochemistry, Genetics and Molecular Biology | 4 | 13% |
Immunology and Microbiology | 3 | 10% |
Economics, Econometrics and Finance | 2 | 6% |
Other | 5 | 16% |
Unknown | 1 | 3% |